Market News & Trends
Oragenics Announces Approval to Initiate Phase 2 Concussion Drug Trial
Oragenics, Inc. recently announced it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase 2 clinical trial evaluating…
Alzamend Neuro Initiates First Phase 2 Trial of AL001 “Lithium in Brain” Study
Alzamend Neuro, Inc. recently today announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy…
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
Invivyd, Inc. recently announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs) who are treating active measles…
ABLi Therapeutics Launches With a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
ABLi Therapeutics recently launched with the mission of developing its lead product candidate, Risvodetinib (ABLi-148009), as a potential disease-modifying therapy for Parkinson’s and Parkinson’s-related diseases…
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated With Intranasal Foralumab
Tiziana Life Sciences, Ltd. recently announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from…
HIV Market to Surpass $32 Billion in 2033
The human immunodeficiency virus (HIV) market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 1.9%…
Colorcon & ASHA Cellulose Announce New Partnership to Support the Development & Manufacture of Barrier Membrane Formulations for the Pharmaceutical & Nutraceutical Industries
Colorcon recently announced an exclusive partnership with ASHA Cellulose, a leading provider of organo-soluble Ethyl cellulose polymers widely used in the pharmaceutical and dietary supplement…
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Toward Anti-Fibrotic Effect of GRI-0621 in First 12 Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently reported interim biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). Additionally, management…
Amneal & Apiject to Expand Sterile & Blow-Fill-Seal Capabilities for Advanced Pharmaceutical Manufacturing in the US
Amneal Pharmaceuticals, Inc. and Apiject Systems, Corp. recently announced a strategic collaboration to expand domestic production of Apiject’s BFS-based injectable platform at Amneal’s Brookhaven, NY…
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
Conduit Pharmaceuticals Inc. recently announced the filing of a new composition of matter patent covering a novel solid form of AZD5904, a clinical-stage myeloperoxidase (MPO)…
Aenova Launches Aenovation(TM) Program to Accelerate Pharmaceutical Development
Aenova, a leading contract development and manufacturing organization (CDMO) in the global pharmaceutical supply chain, recently announced the launch of its innovative Aenovation(TM) program. This…
Sitryx Nominates Novel Oral MTHFD2 Inhibitor for Clinical Development in Psoriatic Arthritis
Sitryx Therapeutics recently announced the nomination of SIT-047, a novel, oral MTHFD2 inhibitor, as the latest development candidate from its proprietary pipeline to progress to…
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy Candidate
Opus Genetics, Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment…
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis & Other Inflammatory Bowel Diseases
Palisade Bio, Inc. recently announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients…
Vetter Prioritizes Continuity & Action in its Sustainability Efforts
Vetter published its fourth annual sustainability report. The report shows that the family-owned business is actively pursuing ambitious sustainability goals in climate protection, social responsibility,…
Aptar CSP Technologies Expands Service Offerings With Launch of cGMP Early Stage Clinical Manufacturing Site for Tablet & Capsule-Based Drug Products
Aptar CSP Technologies, part of AptarGroup, Inc. and a global leader in active material science solutions, announced the expansion of its service offerings with the…
Roquette Announces New Organization Following Acquisition of IFF Pharma Solutions
Roquette recently announced a new organization following the successful acquisition of IFF Pharma Solutions announced on May 1. The new organization is designed to enhance…
Can-Fite Has Raised $175 Million for the Development of Namodenoson & Piclidenoson
Can-Fite BioPharma Ltd. recently announced it has raised $175 million in funding to date. These funds have enabled the advancement of its lead drug candidates,…
Immutep’s Efti in Combination With KEYTRUDA Drives Strong Overall Survival in Head & Neck Cancer With CPS <1
Immutep Limited recently announced an excellent median Overall Survival (OS) of 17.6 months has been achieved in Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb…
Moleculin Bolsters Annamycin Intellectual Property Portfolio With Granting of Two New U.S. Patents
Moleculin Biotech, Inc. recently announced the US Patent and Trademark Office (USPTO) has granted two additional US patents with claims covering Annamycin. US patent number…